KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bausch Health Companies (BHC) Cash & Equivalents (2016 - 2025)

Bausch Health Companies' Cash & Equivalents history spans 17 years, with the latest figure at $1.3 billion for Q3 2025.

  • For Q3 2025, Cash & Equivalents rose 81.92% year-over-year to $1.3 billion; the TTM value through Sep 2025 reached $1.3 billion, up 81.92%, while the annual FY2024 figure was $1.2 billion, 24.71% up from the prior year.
  • Cash & Equivalents for Q3 2025 was $1.3 billion at Bausch Health Companies, down from $1.7 billion in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $1.7 billion in Q2 2025 and bottomed at $486.0 million in Q3 2022.
  • The 5-year median for Cash & Equivalents is $690.0 million (2021), against an average of $829.1 million.
  • The largest annual shift saw Cash & Equivalents tumbled 58.53% in 2023 before it soared 190.25% in 2025.
  • A 5-year view of Cash & Equivalents shows it stood at $582.0 million in 2021, then fell by 3.09% to $564.0 million in 2022, then skyrocketed by 67.91% to $947.0 million in 2023, then increased by 24.71% to $1.2 billion in 2024, then rose by 10.75% to $1.3 billion in 2025.
  • Per Business Quant, the three most recent readings for BHC's Cash & Equivalents are $1.3 billion (Q3 2025), $1.7 billion (Q2 2025), and $1.1 billion (Q1 2025).